Posters

Anti-VEGF therapy efficacy and correlations of visual acuity in patients with neovascular AMD and pigment epithelium detachment

Poster Details

First Author: A.Fursova RUSSIA

Co Author(s):    M. Tarasov   N. Chubar   M. Vasilyeva                       

Abstract Details



Purpose:

To study visual acuity (VA) and central retinal thickness (CRT) changes and correlations of VA with different parameters in patients with neovascular age-related macular degeneration (nAMD) and pigment epithelium detachment (PED) treated with anti-VEGFs.

Setting:

Novosibirsk state region hospital

Methods:

100 patients (100 eyes) with nAMD were included to the study, mean age ± SD 71.1 ± 8.5 years, mean disease duration 7 ± 3.9 years, mean best-corrected visual acuity (BCVA) 0.236 ± 0.19, mean central retinal thickness (CRT) 356.3 ± 65.5 μm. There were 50 patients with PED (73.06 ± 9.3 years, disease duration 6.7 ± 3.55 years), and 50 patients without PED (69.2 ± 7.3 years, disease duration 7.3 ± 4.2 years). The two groups were age- and sex-matched (p>0.05). All patients received intravitreal anti-VEGF treatment (ranibizumab) according 3 + PRN treatment scheme (3 monthly injections followed by “pro re nata”). Follow-up was 12 months analysis was performed using Statistica 6.0 software. Comparative group analysis (using Wilcoxon and Mann-Whitney criteria) and Pearson’s correlation analysis were conducted.

Results:

Mean number of injections in patients with PED was 5.7 ± 2.5 compared to 3.5 ± 1.2 injections in patients without PED (р < 0.05). Baseline VA was 2 times higher in patients without PED than in patients without PED – 0.32 ± 0.21 vs 0.14 ± 0.1 (р < 0.05) and significantly increased by the end of follow-up – 0.52 ± 0.28 vs 0.62 ± 0.28, respectively. CRT did not significantly differ between the groups. Baseline VA negatively associated with presence of PED (r = -0.61, р < 0.05). VA after 3 “loading” doses negatively (r = -0.69, р < 0.05) associated with disease duration and positively – with baseline VA (r = 0.7, р < 0.05). Final VA in patients with PED was associated with baseline VA (r = 0.59, р < 0.05), VA after 4th injection (r = 0.84, р < 0.05) and baseline CRT (r = 0.60, р < 0.05).

Conclusions:

Baseline and final VA was significantly lower in patients with nAMD and PED. Anti-VEGF therapy was effective in the treatment of nAMD irrespective of PED presence. A number of correlations of VA at different timepoints was revealed

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy